Korea Investment CORP Acquires 7,105 Shares of Gilead Sciences, Inc. $GILD

Korea Investment CORP raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,358,423 shares of the biopharmaceutical company’s stock after purchasing an additional 7,105 shares during the period. Korea Investment CORP owned approximately 0.11% of Gilead Sciences worth $166,733,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its stake in Gilead Sciences by 52.1% in the third quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 78,494 shares of the biopharmaceutical company’s stock valued at $8,713,000 after purchasing an additional 26,882 shares in the last quarter. Aviva PLC increased its stake in Gilead Sciences by 5.4% in the fourth quarter. Aviva PLC now owns 1,156,738 shares of the biopharmaceutical company’s stock valued at $141,978,000 after purchasing an additional 59,782 shares in the last quarter. Cookson Peirce & Co. Inc. increased its stake in Gilead Sciences by 249.1% in the third quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock valued at $1,115,000 after purchasing an additional 7,168 shares in the last quarter. NewEdge Wealth LLC increased its position in shares of Gilead Sciences by 2.9% during the third quarter. NewEdge Wealth LLC now owns 619,690 shares of the biopharmaceutical company’s stock worth $75,962,000 after acquiring an additional 17,284 shares in the last quarter. Finally, Nordea Investment Management AB increased its position in shares of Gilead Sciences by 16.5% during the fourth quarter. Nordea Investment Management AB now owns 5,138,699 shares of the biopharmaceutical company’s stock worth $630,056,000 after acquiring an additional 726,101 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on GILD shares. Citigroup increased their price objective on shares of Gilead Sciences from $156.00 to $165.00 and gave the stock a “buy” rating in a research report on Monday, April 13th. Truist Financial reissued a “buy” rating and set a $157.00 price objective (up from $155.00) on shares of Gilead Sciences in a research report on Friday, May 8th. The Goldman Sachs Group increased their price objective on shares of Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a research report on Friday, April 17th. Mizuho increased their price objective on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Finally, Barclays started coverage on shares of Gilead Sciences in a research report on Friday, February 20th. They set an “equal weight” rating and a $155.00 price objective for the company. Twenty-five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $156.93.

Gilead Sciences Stock Performance

Shares of GILD opened at $125.59 on Friday. Gilead Sciences, Inc. has a 12 month low of $104.46 and a 12 month high of $157.29. The firm has a fifty day simple moving average of $133.16 and a 200 day simple moving average of $134.28. The stock has a market capitalization of $155.93 billion, a price-to-earnings ratio of 17.11 and a beta of 0.31. The company has a current ratio of 1.97, a quick ratio of 1.77 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping the consensus estimate of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same quarter in the prior year, the company posted $1.81 earnings per share. The firm’s revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. Research analysts forecast that Gilead Sciences, Inc. will post -0.79 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be paid a $0.82 dividend. The ex-dividend date is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead and Merck reported positive topline Phase 3 results for their once-weekly oral HIV regimen, a potentially important catalyst for Gilead’s HIV franchise and long-term growth. Is Gilead (GILD) One of the Top Large Cap Value Stocks to Buy Now?
• Positive Sentiment: Bernstein reiterated a Buy view on Gilead, and unusual call option activity suggests traders are positioning for upside ahead of additional catalysts. Gilead Sciences (GILD) Gets a Buy from Bernstein
• Positive Sentiment: The company advanced a Phase 2 study of denikitug in difficult-to-treat colorectal cancer, adding another pipeline readout that could broaden Gilead’s oncology prospects. Gilead Advances Denikitug Trial in Tough-to-Treat Colorectal Cancer
• Positive Sentiment: Gilead is donating remdesivir to Uganda to support Ebola response efforts, reinforcing the company’s reputation in infectious disease care and public-health leadership. Gilead Mobilizes Rapid Donation of Remdesivir to Support Ebola Response, Building on Decade-Long Commitment to Outbreak Relief
• Neutral Sentiment: Gilead and the Gilead Foundation announced about $3 million in funding with the National AIDS Memorial for HIV/AIDS education and leadership initiatives, a brand-building effort with limited near-term earnings impact. National AIDS Memorial and the Gilead Foundation Launch Major Investment to Expand HIV/AIDS Education and Community Leadership
• Neutral Sentiment: Erste Group slightly lowered its FY2026 earnings estimate for Gilead, but the revision was small and stays close to the broader loss expectations already in place. Gilead Advances Denikitug Trial in Tough-to-Treat Colorectal Cancer
• Negative Sentiment: Recent commentary suggests Gilead’s stock has pulled back from its 50-day and 200-day moving averages, indicating some short-term technical pressure despite the positive pipeline news.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the completion of the sale, the insider owned 125,779 shares in the company, valued at $16,513,524.91. This trade represents a 18.21% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction on Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the sale, the chief financial officer owned 173,191 shares of the company’s stock, valued at approximately $22,907,973.57. This represents a 1.70% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 68,000 shares of company stock worth $9,047,570 over the last quarter. 0.30% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.